Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis

Free Radical Biology and Medicine

Volumn 115, Issue , 2018, Pages 80-91

  Calabrese, Vittorio ^a   Santoro, Aurelia ^b   Monti, Daniela ^c   Crupi, Rosalia ^d   Di Paola, Rosanna ^d   Latteri, Saverio ^a   Cuzzocrea, Salvatore ^d   Zappia, Mario ^a   Giordano, James ^e   Calabrese, Edward J ^f   Franceschi, Claudio ^g  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MASSACHUSETTS   (United States)

^g IRCCS   (Italy)

Author keywords

Aging; Hormesis; Inflammaging; Inflammation; Neuroinflammation; Parkinson's Disease

Indexed keywords

CHEMOKINE; CYTOKINE;

ADAPTATION; AGING; ASTROCYTE; BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; DENDRITIC CELL; GENETIC RISK; HUMAN; INFLAMMAGING; INTESTINE FLORA; LYMPHOCYTE; MACROPHAGE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; CELL AGING; IMMUNOLOGY; INFLAMMATION; NEUROGENIC INFLAMMATION; PHYSIOLOGY;

AGING; ANIMALS; CELLULAR SENESCENCE; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; NEUROGENIC INFLAMMATION; PARKINSON DISEASE;

EID: 85035339307     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.10.379     Document Type: Review

References (178)

1. Dickson, D.W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K.A., Frigerio, R., Burnett, M., Parisi, J.E., Klos, K.J., Ahlskog, J.E., Neuropathology of non-motor features of Parkinson disease. Park. Relat. Disord. 3 (2009), S1–S5, 10.1016/S1353-8020(09)70769-2.
2. Blaylock, R., Parkinson's disease: microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. Surg. Neurol. Int., 8(1), 2017, 65.
3. Ascherio, A., Schwarzschild, M.A., The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 15 (2016), 1257–1272.
4. Nalls, M.A., Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46 (2014), 989–993.
5. Ottaviani, E., Franceschi, C., A new theory on the common evolutionary origin of natural immunity, inflammation and stress response: the invertebrate phagocytic immunocyte as an eye-witness. Domest. Anim. Endocrinol. 15 (1998), 291–296.
6. Franceschi, C., Bonafè, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., De Benedictis, G., Inflamm-aging: an evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 908 (2000), 244–254, 10.1111/j.1749-6632.2000.tb06651.x.
7. Franceschi, C., Campisi, J., Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 69 (2014), S4–S9, 10.1093/gerona/glu057.
8. Kennedy, B.K., Berger, S.L., Brunet, A., Campisi, J., Maria, A., Epel, E.S., Franceschi, C., Lithgow, G.J., Morimoto, R.I., Pessin, J.E., Rando, T.A., Richardson, A., Schadt, E.E., Wyss-Coray, T., Richard, I., Aging: a common driver of chronic diseases and a target for novel interventions. Cell 159 (2014), 709–713, 10.1016/j.cell.2014.10.039.
9. Franceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M.P., Invidia, L., Celani, L., Scurti, M., Cevenini, E., Castellani, G.C., Salvioli, S., Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 128 (2007), 92–105, 10.1016/j.mad.2006.11.016.
10. Bonafè, M., Olivieri, F., Cavallone, L., Giovagnetti, S., Mayegiani, F., Cardelli, M., Pieri, C., Marra, M., Antonicelli, R., Lisa, R., Rizzo, M.R., Paolisso, G., Monti, D., Franceschi, C., A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur. J. Immunol. 31 (2001), 2357–2361.
11. Gangemi, S., Basile, G., Monti, D., Merendino, R.A., Di Pasquale, G., Bisignano, U., Nicita-Mauro, V., Franceschi, C., Age-related modifications in circulating IL-15 levels in humans. Mediat. Inflamm. 4 (2005), 245–247.
12. Gerli, R., Monti, D., Bistoni, O., Mazzone, A.M., Peri, G., Cossarizza, A., Di Gioacchino, M., Cesarotti, M.E., Doni, A., Mantovani, A., Franceschi, C., Paganelli, R., Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians. Mech. Ageing Dev. 121 (2000), 37–46.
13. Genedani, S., Filaferro, M., Carone, C., Ostan, R., Bucci, L., Cevenini, E., Franceschi, C., Monti, D., Influence of f-MLP, ACTH(1-24) and CRH on in vitro chemotaxis of monocytes from centenarians. Neuroimmunomodulation 15 (2008), 285–289, 10.1159/000156472.
14. Meazza, C., Vitale, G., Pagani, S., Castaldi, D., Ogliari, G., Mari, D., Laarej, K., Tinelli, C., Bozzola, M., Common adipokine features of neonates and centenarians. J. Pediatr. Endocrinol. Metab. 24 (2011), 953–957.
15. Collino, S., Montoliu, I., Martin, F.P., Scherer, M., Mari, D., Salvioli, S., Bucci, L., Ostan, R., Monti, D., Biagi, E., Brigidi, P., Franceschi, C., Rezzi, S., Metabolic signatures of extreme longevity in Northern Italian centenarians reveal a complex remodeling of lipids, amino acids, and gut microbiota metabolism. PLoS One, 8, 2013, e56564, 10.1371/journal.pone.0056564.
16. Morrisette-Thomas, V., Cohen, A.A., Fülöp, T., Riesco, É., Legault, V., Li, Q., Milot, E., Dusseault-Bélanger, F., Ferrucci, L., Inflamm-aging does not simply reflect increases in pro-inflammatory markers. Mech. Ageing Dev. 139 (2014), 49–57, 10.1016/j.mad.2014.06.005.
17. Monti, D., Ostan, R., Borelli, V., Castellani, G., Franceschi, C., Inflammaging and human longevity in the omics era. Mech. Ageing Dev. S0047-6374:16 (2016), 30261–30265, 10.1016/j.mad.2016.12.008.
18. Sulzer, D., Surmeier, D.J., Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov. Disord. 28 (2013), 41–50.
19. Leverenz, J.B., Quinn, J.F., Zabetian, C., Zhang, J., Montine, K.S., Montine, T.J., Cognitive impairment and dementia in patients with Parkinson disease. Curr. Top. Med. Chem. 9 (2009), 903–912.
20. Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., Kirkland, J.L., Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123 (2013), 966–972.
21. O'Mahony, S.M., Clarke, G., Borre, Y.E., Dinan, T.G., Cryan, J.F., Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav. Brain Res. J. S0166-4328:14 (2014), 00476–00478 (pii:).
22. Davis, M.Y., Johnson, C.O., Leverenz, J.B., Weintraub, D., Trojanowski, J.Q., Chen-Plotkin, A., Van Deerlin, V.M., Quinn, J.F., Chung, K.A., Peterson-Hiller, A.L., Rosenthal, L.S., Dawson, T.M., Albert, M.S., Goldman, J.G., Stebbins, G.T., Bernard, B., Wszolek, Z.K., Ross, O.A., Dickson, D.W., Eidelberg, D., Mattis, P.J., Niethammer, M., Yearout, D., Hu, S.C., Cholerton, B.A., Smith, M., Mata, I.F., Montine, T.J., Edwards, K.L., Zabetian, C.P., Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurol. 73:10 (2016), 1217–1224, 10.1001/jamaneurol.2016.2245.
23. Amor, S., Inflammation in neurodegenerative disease. Immunology 129 (2014), 154–169.
24. Ransohoff, R.M., How neuroinflammation contributes to neurodegeneration. Science 353 (2016), 777–783.
25. Herrero, M.-T., Estrada, C., Maatouk, L., Vyas, S., Inflammation in Parkinson's disease: role of glucocorticoids. Front. Neuroanat., 9, 2015, 32, 10.3389/fnana.2015.00032.
26. Xie, X., Luo, X., Liu, N., Li, X., Lou, F., Zheng, Y., Ren, Y., Monocytes, microglia, and CD200-CD200R1 signaling are essential in the transmission of inflammation from the periphery to the central nervous system. J. Neurochem. 141:2 (2017), 222–235, 10.1111/jnc.13972.
27. Gao, H.M., Hong, J.S., Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 29:8 (2008), 357–365.
28. Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., Derecki, N.C., Castle, D., Mandell, J.W., Lee, K.S., Structural and functional features of central nervous system lymphatic vessels. Nature 523 (2015), 337–341.
29. Dias, V., Junn, E., Mouradian, M.M., The role of oxidative stress in Parkinson's disease. J. Park. Dis. 3 (2013), 461–491.
30. Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D.A., Giuffrida Stella, A.M., Nitric oxide in the CNS: neuroprotection versus neurotoxicity. Nat. Neurosci. 8 (2007), 766–775.
31. De Grey, A.D.N.J., Reactive oxygen species production in the mitochondrial matrix: implications for the mechanism of mitochondrial mutation accumulation. Rejuvenation Res. 8 (2005), 13–17.
32. Rose, G., Santoro, A., Salvioli, S., Mitochondria and mitochondria-induced signalling molecules as longevity determinants. Mech. Ageing Dev. S0047-6374:16 (2016), 30173–30177, 10.1016/j.mad.2016.12.002 (pii:).
33. Greenamyre, J.T., Sanders, L.H., Gasser, T., Fruit flies, bile acids, and Parkinson disease: a mitochondrial connection?. Neurology 85:10 (2015), 838–839, 10.1212/WNL.0000000000001912.
34. Schapira, A.H., Cooper, J.M., Dexter, D., Jenner, P., Clark, J.B., Marsden, C.D., Mitochondrial complex I deficiency in Parkinson's disease. Lancet, 1, 1989, 1269.
35. Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G., Anandatheerthavarada, H.K., Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283 (2008), 9089–9100.
36. Zheng, B., Liao, Z., Locascio, J.J., Lesniak, K.A., Roderick, S.S., Watt, M.L., Eklund, A.C., Zhang-James, Y., Kim, P.D., Hauser, M.A., Grünblatt, E., Moran, L.B., Mandel, S.A., Riederer, P., Miller, R.M., Federoff, H.J., Wüllner, U., Papapetropoulos, S., Youdim, M.B., Cantuti-Castelvetri, I., Young, A.B., Vance, J.M., Davis, R.L., Hedreen, J.C., Adler, C.H., Beach, T.G., Graeber, M.B., Middleton, F.A., Rochet, J.C., Scherzer, C.R., Global PD Gene Expression (GPEX) Consortium. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med., 2, 2010 (52ra73).
37. Eschbach, J., von Einem, B., Müller, K., Bayer, H., Scheffold, A., Morrison, B.E., Rudolph, K.L., Thal, D.R., Witting, A., Weydt, P., Otto, M., Fauler, M., Liss, B., McLean, P.J., Spada, A.R., Ludolph, A.C., Weishaupt, J.H., Danzer, K.M., Mutual exacerbation of peroxisome proliferator-activated receptor gamma coactivator 1alpha deregulation and alpha-synuclein oligomerization. Ann. Neurol. 77 (2015), 15–32.
38. Bose, A., Beal, M.F., Mitochondrial dysfunction in Parkinson's disease. J. Neurochem. 139 (2016), 216–231.
39. Kstrand, M.I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F.S., Trifunovic, A., Hoffer, B., Cullheim, S., Mohammed, A.H., Olson, L., Larsson, N.G., Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. USA 104:4 (2007), 1325–1330.
40. Nordströma, U., Beauvais, G., Ghosh, A., Pulikkaparambil Sasidharan, B.C., Lundblad, M., Fuchs, J., Joshi, R.L., Lipton, J.W., Roholt, A., Medicetty, S., Feinstein, T.N., Steiner, J.A., Escobar Galvis, M.L., Prochiantz, A., Brundin, P., Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Neurobiol. Dis. 73 (2015), 70–82.
41. Sossi, V., de la Fuente-Fernández, R., Holden, J.E., Schulzer, M., Ruth, T.J., Stoessl, J., Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J. Cereb. Blood Flow Metab. 24 (2004), 869–876.
42. Kordower, J.H., Olanow, C.W., Dodiya, H.B., Chu, Y., Beach, T.G., Adler, C.H., Halliday, G.M., Bartus, R.T., Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136 (2013), 2419–2431.
43. Lamberts, J.T., Hildebrandt, E.N., Brundin, P., Spreading of alpha-synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis. Neurobiol. Dis. 77 (2015), 276–283.
44. Vitale, N., Kisslinger, A., Paladino, S., Procaccini, C., Matarese, G., Pierantoni, G.M., Mancini, F.P., Tramontano, D., Resveratrol couples apoptosis with autophagy in UVB-irradiated HaCaT cells. PLoS One, 8(11), 2013, e80728, 10.1371/journal.pone.0080728 (eCollection 2013).
45. Harman, D., Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11 (1956), 298–300.
46. Salvioli, S., Capri, M., Valensin, S., Tieri, P., Monti, D., Ottaviani, E., Franceschi, C., Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr. Pharm. Des. 12 (2006), 3161–3171.
47. Barzilai, A., Rotman, G., Shiloh, Y., ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair 1 (2002), 3–25.
48. Martin, O.A., Redon, C.E., Dickey, J.S., Nakamura, A.J., Bonner, W.M., Para-inflammation mediates systemic DNA damage in response to tumor growth. Commun. Integr. Biol. 4 (2011), 78–81.
49. Bonafé, M., Storci, G., Franceschi, C., Inflamm-aging of the stem cell niche: breast cancer as a paradigmatic example: breakdown of the multi-shell cytokine network fuels cancer in aged people. Bioessays 34 (2012), 40–49.
50. Canugovi, C., Misiak, M., Ferrarelli, L.K., Croteau, D.L., Bohr, V.A., The role of DNA repair in brain related disease pathology. DNA Repair 12:8 (2013), 578–587.
51. Morris, L.G., Veeriah, S., Chan, T.A., Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 29 (2010), 3453–3464, 10.1038/onc.2010.127.
52. Brozovic, A., Damrot, J., Tsaryk, R., Helbig, L., Nikolova, T., Hartig, C., Osmak, M., Roos, W.P., Kaina, B., Fritz, G., Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response. Mutat. Res. 670 (2009), 32–41.
53. Ogino, M., Ichimura, M., Nakano, N., Minami, A., Kitagishi, Y., Matsuda, S., Roles of PTEN with DNA repair in Parkinson's disease. Int. J. Mol. Sci., 17(6), 2016, 10.3390/ijms17060954.
54. Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., de Bernard, M., Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One, 8, 2013, 31.
55. Lu, M., Sun, X.L., Qiao, C., Liu, Y., Ding, J.H., Hu, G., Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation. Neurobiol. Aging 35 (2014), 421–430.
56. Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., Zhou, R., Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160 (2015), 62–73.
57. Mao, Z., Liu, C., Ji, S., Yang, Q., Ye, H., Han, H., Xue, Z., The NLRP3 inflammasome is involved in the pathogenesis of Parkinson's disease in rats. Neurochem. Res. 42:4 (2017), 1104–1115, 10.1007/s11064-017-2185-0.
58. Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkmann, J., Schrag, A.E., Lang, A.E., Parkinson disease. Nat. Rev. Dis. Prim., 3(17013), 2017, 10.1038/nrdp.2017.13.
59. Pissadaki, E.K., Bolam, J.P., The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front. Comput. Neurosci., 7, 2013, 13.
60. Surmeier, D.J., Schumacker, P.T., Guzman, J.D., Ilijic, E., Yang, B., Zampese, E., Calcium and Parkinson's disease. Biochem. Biophys. Res. Commun. 483 (2017), 1013–1019.
61. Mosharov, E.V., Larsen, K.E., Kanter, E., Phillips, K.A., Wilson, K., Schmitz, Y., Krantz, D.E., Kobayashi, K., Edwards, R.H., Sulzer, D., Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62 (2009), 218–229.
62. Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., Vila, M., Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30 (2010), 12535–12544.
63. Ransohoff, R.M., Cardona, A.E., The myeloid cells of the central nervous system parenchyma. Nature 468 (2010), 253–262.
64. Lull, M.E., Block, M.L., Microglial activation and chronic neurodegeneration. Neurotherapeutics 7:4 (2010), 354–365, 10.1016/j.nurt.2010.05.014.
65. Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., Hashizume, Y., Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 106 (2003), 518–526.
66. Knott, C., Stern, G., Wilkin, G.P., Inflammatory regulators in Parkinson's disease: i NOS, Lipocortin-1, and cyclooxygenase-1 and -2. Mol. Cell. Neurosci. 16 (2000), 724–739.
67. Collins, L.M., Toulouse, A., Connor, T.J., Nolan, Y.M., Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 62:7 (2012), 2154–2168.
68. Banati, R.B., Daniel, S.E., Blunt, S.B., Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13:2 (1998), 221–227.
69. Yu, Z., Xu, X., Xiang, Z., Zhou, J., Zhang, Z., Hu, C., He, C., Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One, 5(4), 2010, e9956, 10.1371/journal.pone.0009956.
70. Venkateshappa, C., Harish, G., Mythri, R.B., Mahadevan, A., Bharath, M.M., Shankar, S.K.L., Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochem. Res. 37 (2012), 358–369.
71. Ben Haim, L., Carrillo-de Sauvage, M.A., Ceyzeriat, K., Scartin, C., Elusive roles for reactive astrocytes in neurodegenerative diseases. Front. Cell. Neurosci., 9, 2015, 278.
72. Mena, M.A., Garcia De Yebenes, J., Glial cells as players in parkinsonism: the “good”, the “bad”, and the “mysterious” glia. Neuroscientist 14 (2008), 544–560.
73. Verkhratsky, A., Zorec, R., Rodriguez, J.J., Parpura, V., Pathobiology of neurodegeneration: the role for astroglia. Opera Med. Physiol. 1 (2016), 13–22.
74. Zhang, Y., Barres, B.A., Astrocyte heterogeneity: an underappreciated topic in neurobiology. Curr. Opin. Neurobiol. 20 (2010), 588–594.
75. Chinta, S.J., Lieu, C.A., Demaria, M., Laberge, R.M., Campisi, J., Andersen, J.K., Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson's disease?. J. Intern. Med. 273:5 (2013), 429–436, 10.1111/joim.12029.
76. Sorci, G., Bianchi, R., Riuzzi, F., Tubaro, C., Arcuri, C., Giambanco, I., Donato, R., S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc. Psychiatry Neurol., 2010, 2010 (2090-0163).
77. Bianchi, R., Adami, C., Giambanco, I., Donato, R., S100B binding to RAGE in microglia stimulates COX-2 expression. J. Leukoc. Biol. 81 (2007), 108–118.
78. Gomes, M.Z., Raisman-Vozari, R., Del-Bel, E., A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res. 1203 (2008), 160–169.
79. Dehmer, T., Lindenau, J., Haid, S., Dichgans, J., Schulz, J.B., Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem 74 (2000), 2213–2216.
80. Lee, H.J., Suk, J.E., Patrick, C., Bae, E.J., Cho, J.H., Rho, S., Hwang, D., Masliah, E., Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285 (2010), 9262–9272.
81. Nedergaard, M., Rodrıguez, J.J., Verkhratsky, A., Glial calcium and diseases of the nervous system. Cell Calcium 47 (2010), 140–149.
82. Hauwel, M., Furon, E., Canova, C., Griffiths, M., Neal, J., Gasque, P., Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglía, astrocytes, “protective” glial stem cells and stromal ependymal cells. Brain Res. Rev. 48 (2005), 220–233, 10.1016/j.brainresrev.2004.12.012.
83. S.S. Ousman, P. Kubes, Immune surveillance in the central nervous system. Nat. Neurosci., vol. 15(8), 2012, pp. 1096–1101. 〈 http://dx.doi.org/10.1038/nn.3161〉. Review. Erratum in: Nat Neurosci. vol. 17(9), 2014, p. 1286. PubMed PMID: 22837040.
84. Sarkar, A., Mitra, S., Mehta, S., Raices, R., Wewers, M.D., Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS One, 4, 2009, e7140, 10.1371/journal.pone.0007140.
85. Gulinelli, S., Salaro, E., Vuerich, M., Bozzato, D., Pizzirani, C., Bolognesi, G., Idzko, M., Di Virgilio, F., Ferrari, D., IL-18 associates to microvesicles shed from human macrophages by a LPS/TLR-4 independent mechanism in response to P2X receptor stimulation. Eur. J. Immunol. 42 (2012), 3334–3345, 10.1002/eji.201142268.
86. Yamate, J., Ishimine, S., Izawa, T., Kumagai, D., Kuwamura, M., Macrophage populations and expressions of regulatory proinflammatory factors in the rat meninx under lipopolysaccharide treatment in vivo and in vitro. Histol. Histopathol. 24 (2009), 13–24.
87. Prodinger, C., Bunse, J., Krüger, M., Schiefenhövel, F., Brandt, C., Laman, J.D., Greter, M., Immig, K., Heppner, F., Becher, B., Bechmann, I., CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol. 121 (2011), 445–458, 10.1007/s00401-010-0774-y.
88. D'Agostino, P.M., Gottfried-Blackmore, A., Anandasabapathy, N., Bulloch, K., Brain dendritic cells: biology and pathology. Acta Neuropathol. 124:5 (2012), 599–614, 10.1007/s00401-012-1018-0.
89. Schlitzer, A., McGovern, N., Ginhoux, F., Dendritic cells and monocyte-derived cells: two complementary and integrated functional systems. Semin. Cell Dev. Biol. 41 (2015), 9–22, 10.1016/j.semcdb.2015.03.011.
90. Colton, C.A., Immune heterogeneity in neuroinflammation: dendritic cells in the brain. J. Neuroimmune Pharmacol. 8:1 (2013), 145–162, 10.1007/s11481-012-9414-8.
91. McMahon, E.J., Bailey, S.L., Miller, S.D., CNS dendritic cells: critical participants in CNS inflammation?. Neurochem. Int. 49 (2007), 195–203, 10.1016/j.neuint.2006.04.004.
92. Ciaramella, A., Salani, F., Bizzoni, F., Pontieri, F.E., Stefani, A., Pierantozzi, M., Assogna, F., Caltagirone, C., Spalletta, G., Bossù, P., Blood dendritic cell frequency declines in idiopathic Parkinson's disease and is associated with motor symptom severity. PLoS One, 11, 2013, e65352, 10.1371/journal.pone.0065352.
93. Phani, S., Loike, J.D., Przedborski, S., Neurodegeneration and Inflammation in Parkinson's disease. Park. Relat. Disord. 1851 (2012), 207–209.
94. Saunders, J.A.H., Estes, K.A., Kosloski, L.M., CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J. Neuroimmune Pharmacol. 7:4 (2012), 927–938.
95. Hisanaga, K., Asagi, M., Itoyama, Y., Iwasaki, Y., Increase in peripheral CD bright? CD8 dull T cells in Parkinson disease. Arch. Neurol. 58 (2001), 1580–1583.
96. Calopa, M., Bas, J., Call.en, A., Mestre, M., Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol. Dis. 38:1 (2010), 1–7.
97. Prigione, A., Isaias, I.U., Galbussera, A., Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. Park. Relat. Disord. 15:4 (2009), 327–328.
98. Shimoji, M., Pagan, F., Healton, E.B., Mocchetti, I., CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox. Res. 16:3 (2009), 318–328.
99. Shimoji, M., Pagan, F., Healton, E.B., Mocchetti, Italo, CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox. Res. 16:13 (2009), 318–328.
100. Shi, M., Bradner, J., Hancock, A.M., Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69:3 (2011), 570–580.
101. Blum-Degena, D., M¨uller, T., Kuhn, W., Gerlach, M., Przuntek, H., Riederer, P., Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202 (1995), 17–20.
102. Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., Nagatsu, T., Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211 (1996), 13–16.
103. Vawter, M.P., Dillon-Carter, O., Tourtellotte, W.W., Carvey, P., Freed, W.J., TGFβ1 and TGFβ2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp. Neurol. 142 (1996), 313–322.
104. Koziorowski, D., Tomasiuk, R., Szlufik, S., Friedman, A., Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 60 (2012), 762–766.
105. Rocha, N.P., Teixeira, A.L., Scalzo, P.L., Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Mov. Disord. 29 (2014), 527–531.
106. Katsarou, Z., Bostantjopoulou, S., Hatzizisi, O., Giza, E., Soler-Cardona, A., Kyriazis, G., Immune factors or depression? Fatigue correlates in Parkinson's disease. Rev. Neurol. 45 (2007), 725–728.
107. Nicoletti, A., Fagone, P., Donzuso, G., Mangano, K., Dibilio, V., Caponnetto, S., Bendtzen, K., Zappia, M., Nicoletti, F., Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. Cytokine 55:2 (2011), 165–167, 10.1016/j.cyto.2011.03.027.
108. Brodacki, B., Staszewski, J., Toczyłowska, B., Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 441 (2008), 158–162.
109. Scalzo, P., K¨ummer, A., Cardoso, F., Teixeira, A.L., Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci. Lett. 468 (2010), 56–58.
110. Chen, H., O'Reilly, E.J., Schwarzschild, M.A., Ascherio, A., Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol. 167 (2008), 90–95.
111. Pereira, J.R., Santos, L.V., Santos, R.M., Campos, A.L., Pimenta, A.L., de Oliveira, M.S., Bacheti, G.G., Rocha, N.P., Teixeira, A.L., Christo, P.P., Scalzo, P.L., IL-6 serum levels are elevated in Parkinson's disease patients with fatigue compared to patients without fatigue. J. Neurol. Sci. 370 (2016), 153–156, 10.1016/j.jns.2016.09.030.
112. Mihara, T., Nakashima, M., Kuroiwa, A., Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. Park. Relat. Disord. 14 (2008), 46–51.
113. Rentzos, M., Nikolaou, C., Andreadou, E., Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol. Scand. 119 (2009), 332–337.
114. Scalzo, P., De Miranda, A.S., Guerra Amaral, D.C., De Carvalho Vilela, M., Cardoso, F., Teixeira, A.L., Serum levels of chemokines in Parkinson's disease. NeuroImmunoModulation 18 (2011), 240–244.
115. Rocha, N.P., Scalzo, P.L., Barbosa, I.G., Souza, M.S., Morato, I.B., Vieira, E.L., Christo, P.P., Teixeira, A.L., Reis, H.J., Cognitive status correlates with CXCL10/IP-10 levels in Parkinson's disease. Park. Dis., 2014, 2014, 903796, 10.1155/2014/903796.
116. Rattan, S.I., Biology of ageing: principles, challenges and perspectives. Rom. J. Morphol. Embryol. 56:4 (2015), 1251–1253 (Review).
117. Castillo-Quan, J.I., Li, L., Kinghorn, K.J., Ivanov, D.K., Tain, L.S., Slack, C., Kerr, F., Nespital, T., Thornton, J., Hardy, J., Bjedov, I., Partridge, L., Lithium promotes longevity through GSK3/NRF2-dependent hormesis. Cell Rep. 15:3 (2016), 638–650, 10.1016/j.celrep.2016.03.041 (PubMed PMID: 27068460; PubMed Central PMCID).
118. Ristow, M., Zarse, K., How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp. Gerontol. 45 (2010), 410–418.
119. Calabrese, E.J., Dhawan, G., Kapoor, R., Iavicoli, I., Calabrese, V., What is hormesis and its relevance to healthy aging and longevity?. Biogerontology 16:6 (2015), 693–707, 10.1007/s10522-015-9601-0.
120. Gaman, L., Stoian, I., Atanasiu, V., Can ageing be slowed?: hormetic and redox perspectives. J. Med. Life 4:4 (2011), 346–351 (Review).
121. Rattan, S.I.S., Hormesis in aging. Ageing Res. Rev. 7:1 (2008), 63–78.
122. Martucci, M., Ostan, R., Biondi, F., Bellavista, E., Fabbri, C., Bertarelli, C., Salvioli, S., Capri, M., Franceschi, C., Santoro, A., The Mediterranean diet and inflammaging within the hormesis paradigm. Nutr. Rev., 2017, 10.1093/nutrit/nux013 (Epubahead of print) (PubMed PMID: 28595318).
123. Mattson, M.P., Son, T.G., Camandola, S., Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Response 5:3 (2007), 174–186, 10.2203/dose-response.07-004.
124. Mattson, M.P., Cheng, A., Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci. 29:11 (2006), 632–639 (Review).
125. Joseph, J.A., Shukitt-Hale, B., Casadesus, G., Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am. J. Clin. Nutr. 81:1 Suppl. (2005), 313S–316S (Review).
126. Huang, P.L., Nitric oxide and cerebral ischemic preconditioning. Cell Calcium 36:3–4 (2004), 323–329.
127. Raefsky, S.M., Mattson, M.P., Adaptive responses of neuronal mitochondria to bioenergetic challenges: roles in neuroplasticity and disease resistance. Free Radic. Biol. Med. 102 (2017), 203–216, 10.1016/j.freeradbiomed.2016.11.045.
128. Stranahan, A.M., Norman, E.D., Lee, K., Cutler, R.G., Telljohann, R.S., Egan, J.M., Mattson, M.P., Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18:11 (2008), 1085–1088, 10.1002/hipo.20470.
129. van den Berg, E., Dekker, J.M., Nijpels, G., Kessels, R.P., Kappelle, L.J., de Haan, E.H., Heine, R.J., Stehouwer, C.D., Biessels, G.J., Cognitive functioning in elderly persons with type 2 diabetes and metabolic syndrome: the Hoorn study. Dement. Geriatr. Cogn. Disord. 26:3 (2008), 261–269, 10.1159/000160959.
130. Gazdzinski, S., Kornak, J., Weiner, M.W., Meyerhoff, D.J., Body mass index and magnetic resonance markers of brain integrity in adults. Ann. Neurol. 63:5 (2008), 652–657, 10.1002/ana.21377.
131. Clarke, G., Mini review: gut microbiota: the neglected endocrine organ. Mol. Endocrinol. 28:8 (2014), 1221–1238.
132. Tremlett, H., Bauer, K.C., Appel-Cresswell, S.F.B., The gut microbiome in human neurological disease: a review. Ann. Neurol., 2017, 10.1002/ana.24901.
133. Mulak, A., Bonaz, B., Brain-gut-microbiota axis in Parkinson's disease. World J. Gastroenterol. 21:37 (2015), 10609–10620.
134. Unger, M.M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Schäfer, K.-H., Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Park. Relat. Disord. 32 (2016), 66–72, 10.1016/j.parkreldis.2016.08.019.
135. Sampson, T.R., Debelius, J.W., Thron, T., Janssen, S., Shastri, G.G., Ilhan, Z.E., Challis, C., Schretter, C.E., Rocha, S., Gradinaru, V., Chesselet, M.F., Keshavarzian, A., Shannon, K.M., Krajmalnik-Brown, R., Wittung-Stafshede, P., Knight, R., Mazmanian, S.K., Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167:6 (2016), 1469–1480 (e12).
136. Vaiserman, A.M., Koliada, A.K., Marotta, F., Gut microbiota: a player in aging and a target for anti-aging intervention. Ageing Res. Rev. 35 (2017), 36–45, 10.1016/j.arr.2017.01.001.
137. Xu, R., Shang, N., Li, P., In vitro and in vivo antioxidant activity of exopolysaccharide fractions from Bifidobacterium animalis RH. Anaerobe 17:5 (2011), 226–231.
138. Xu, M.Q., Cao, H.L., Wang, W.Q., Wang, S., Cao, X.C., Yan, F., Wang, B.M., Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J. Gastroenterol. 21:1 (2015), 102–111.
139. Biagi, E., Nylund, L., Candela, M., Ostan, R., Bucci, L., Pini, E., Nikkïla, J., Monti, D., Satokari, R., Franceschi, C., Brigidi, P., de Vos, W., Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One, 5(5), 2010, e10667, 10.1371/journal.pone.0010667.
140. Biagi, E., Franceschi, C., Rampelli, S., Severgnini, M., Ostan, R., Turroni, S., Consolandi, C., Quercia, S., Scurti, M., Monti, D., Capri, M., Brigidi, P., Candela, M., Gut microbiota and extreme longevity. Curr. Biol. 26 (2016), 1480–1485, 10.1016/j.cub.2016.04.016.
141. Rampelli, S., Candela, M., Turroni, S., Biagi, E., Collino, S., Franceschi, C., O'Toole, P.W., Brigidi, P., Functional metagenomic profiling of intestinal microbiome in extreme ageing. Aging 5:12 (2013), 902–912.
142. Westfall, S., Lomis, N., Kahouli, I., Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. Cell. Mol. Life Sci., 22, 2017, 10.1007/s00018-017-2550-9.
143. Rogers, G.B., Keating, D.J., Young, R.L., Wong, M.L., Licinio, J., Wesselingh, S., From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol. Psychiatry 21:6 (2016), 738–748, 10.1038/mp.2016.50.
144. Cryan, J.F., Dinan, T.G., Mind-altering microorganisms: the impact of the gutmicrobiota on brain and behaviour. Nat. Rev. Neurosci. 13:10 (2012), 701–712, 10.1038/nrn3346.
145. Stone, T.W., Darlington, L.G., The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br. J. Pharmacol. 169:6 (2013), 1211–1227, 10.1111/bph.12230.
146. Keszthelyi, D., Troost, F.J., Masclee, A.A., Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function. Neurogastroenterol. Motil. 21:12 (2009), 1239–1249, 10.1111/j.1365-2982.2009.01370.x (Epub 2009 Jul 28).
147. Kaszaki, J., Erces, D., Varga, G., Szabó, A., Vécsei, L., Boros, M., Kynurenines and intestinal neurotransmission: the role of N-methyl-D-aspartate receptors. J. Neural Transm. 119:2 (2012), 211–223, 10.1007/s00702-011-0658-x.
148. Maddison, D.C., Giorgini, F., The kynurenine pathway and neurodegenerative disease. Semin. Cell Dev. Biol. 40 (2015), 134–141, 10.1016/j.semcdb.2015.03.002.
149. Nelson, G., Wordsworth, J., Wang, C., Jurk, D., Lawless, C., Martin-Ruiz, C., von Zglinicki, T., A senescent cell bystander effect: senescence-induced senescence. Aging Cell 11:2 (2012), 345–349.
150. Baroja-Mazo, A., Martín-Sánchez, F., Gomez, A.I., Martínez, C.M., Amores-Iniesta, J., Compan, V., Barberà-Cremades, M., Yagüe, J., Ruiz-Ortiz, E., Antón, J., Buján, S., Couillin, I., Brough, D., Arostegui, J.I., Pelegrín, P., The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat. Immunol. 15:8 (2014), 738–748.
151. Pinti, M., Cevenini, E., Nasi, M., De Biasi, S., Salvioli, S., Monti, D., Benatti, S., Gibellini, L., Cotichini, R., Stazi, M.A., Trenti, T., Franceschi, C., Cossarizza, A., Circulating mitochondrial DNA increases with age and is a familiar trait: implications for “inflamm-aging”. Eur. J. Immunol. 44:5 (2014), 1552–1562, 10.1002/eji.201343921.2014.
152. Olivieri, F., Rippo, M.R., Monsurrò, V., Salvioli, S., Capri, M., Procopio, A.D., Franceschi, C., MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res. Rev. 12:4 (2013), 1056–1068, 10.1016/j.arr.2013.05.001.
153. Franceschi, C., Garagnani, P., Vitale, G., Capri, M., Salvioli, S., Inflammaging and “Garb-aging”. Trends Endocrinol. Metabol. 0:0 (2016), 2609–2617, 10.1016/j.tem.2016.09.005.
154. Jurk, D., Wilson, C., Passos, J.F., Oakley, F., Correia-Melo, C., Greaves, L., Saretzki, G., Fox, C., Lawless, C., Anderson, R., Hewitt, G., Pender, S.L., Fullard, N., Nelson, G., Mann, J., van de Sluis, B., Mann, D.A., von Zglinicki, T., Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat. Commun., 2, 2014, 4172, 10.1038/ncomms5172.
155. Villeda, S.A., Wyss-Coray, T., The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477:7362 (2011), 90–94.
156. Villeda, S.A., Wyss-Coray, T., The circulatory systemic environment as a modulator of neurogenesis and brain aging. Autoimmun. Rev. 12 (2013), 674–677.
157. Villeda, S.A., Wyss-Coray, T., Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 20:6 (2014), 659–663.
158. Barberi, L., Scicchitano, B.M., De Rossi, M., Bigot, A., Duguez, S., Wielgosik, A., Stewart, C., McPhee, J., Conte, M., Narici, M., Franceschi, C., Mouly, V., Butler-Browne, G., Musarò, A., Age-dependent alteration in muscle regeneration: the critical role of tissue niche. Biogerontology 14:3 (2013), 273–292.
159. Salminen, A., Kaarniranta, K., Kauppinen, A., Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging 4 (2012), 166–175.
160. Youm, Y.H., Grant, R.W., McCabe, L.R., Albarado, D.C., Nguyen, K.Y., Ravussin, A., Pistell, P., Newman, S., Carter, R., Laque, A., Münzberg, H., Rosen, C.J., Ingram, D.K., Salbaum, J.M., Dixit, V.D., Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 18 (2013), 519–532.
161. Alvarez-Castelao, B., Goethals, M., Vandekerckhove, J., Castaño, J.G., Mechanism of cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx state of the N-terminal methionines. Biochim. Biophys. Acta 1843 (2014), 352–365.
162. Furman, D., Chang, J., Lartigue, L., Bolen, C.R., Haddad, F., Gaudilliere, B., Faustin, B., Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat. Med., 23(2), 2017, 10.1038/nm.4267.
163. de Rivero Vaccari, J.P., Dietrich, W.D., Keane, R.W., Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J. Cereb. Blood Flow Metab. Mar. 34:3 (2014), 369–375.
164. Pennisi, M., Crupi, R., Di Paola, R., Ontario, M.L., Bella, R., Calabrese, E.J., Crea, R., Cuzzocrea, S., Calabrese, V., Inflammasomes, hormesis, and antioxidants in neuroinflammation: role of NRLP3 in Alzheimer disease. J. Neurosci. Res. 95 (2017), 1360–1372.
165. Savage, C.D., Lopez-Castejon, G., Denes, A., Brough, D., NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front. Immunol., 3, 2012, 288.
166. Warren Olanow, C., Do prions cause Parkinson disease?: the evidence accumulates. Ann. Neurol., 2014, 10.1002/ana.24098 (Editorial).
167. Lee, H.J., Bae, E.J., Lee, S.J., Extracellular α-synuclein – a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10 (2014), 92–98.
168. Guo, J.L., Lee, V.M., Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med 20 (2014), 130–138.
169. Domert, J., Rao, S.B., Agholme, L., Brorsson, A.C., Marcusson, J., Hallbeck, M., Nath, S., Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol. Dis. 65C (2014), 82–92.
170. Cornelius, C., Trovato Salinaro, A., Scuto, M., Fronte, V., Cambria, M.T., Pennisi, M., Bella, R., Milone, P., Graziano, A., Crupi, R., Cuzzocrea, S., Pennisi, G., Calabrese, V., Cellular stress response, sirtuins and UCP proteins in Alzheimer disease: role of vitagenes. Immun. Ageing, 10, 2013, 41, 10.1186/1742-4933-10-41.
171. Calabrese, V., Cornelius, C., Dinkova-Kostova, A.T., Calabrese, E.J., Mattson, M.P., Cellular stress responses, the hormesis paradigm and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal. 13 (2010), 1763–1811.
172. Edrey, Y.H., Oddo, S., Cornelius, C., Caccamo, A., Calabrese, V., Buffenstein, R., Oxidative damage and amyloid-β metabolism in brain regions of the longest-lived rodents. J. Neurosci. Res. 92 (2014), 195–205.
173. Calabrese, V., Cornelius, C., Cuzzocrea, S., Iavicoli, I., Rizzarelli, E., Calabrese, E.J., Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity. Mol. Asp. Med. 32 (2011), 279–304.
174. Dattilo, S., Mancuso, C., Koverech, G., Di Mauro, P., Ontario, M.L., Petralia, C.C., Petralia, A., Maiolino, L., Serra, A., Calabrese, E.J., Calabrese, V., Heat shock proteins and hormesis in the diagnosis and treatment of neurodegenerative diseases. Immun. Ageing, 2015, 10.1186/s12979-015-0046-8 (eCollection 2015).
175. Calabrese, V., Dattilo, S., Petralia, A., Parenti, R., Pennisi, M., Koverech, G., Calabrese, V., Graziano, A., Monte, I., Maiolino, L., Ferreri, T., Calabrese, E.J., Analytical approaches to the diagnosis and treatment of aging and aging-related disease: redox status and proteomics. Free Radic. Res. 49 (2015), 511–524.
176. Trovato Salinaro, A., Cornelius, C., Koverech, G., Koverech, A., Scuto, M., Lodato, F., Fronte, V., Muccilli, V., Reibaldi, M., Longo, A., Uva, M.G., Calabrese, V., Cellular stress response, redox status, and vitagenes in glaucoma: a systemic oxidant disorder linked to Alzheimer's disease. Front. Pharmacol., 5, 2014, 129, 10.3389/fphar.2014.00129 (eCollection 2014).
177. Calabrese, V., Cornelius, C., Giuffrida, A.M., Calabrese, E.J., Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. Neurochem. Res. 35 (2010), 1880–1915.
178. Calabrese, V., Mancuso, C., Ravagna, A., Perluigi, M., Cini, C., De Marco, C., Butterfield, D.A., Giuffrida Stella, A.M., In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. J. Neurochem. 101 (2007), 709–717.